# A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct07225946/  
OnCo record `nct07225946` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pasritamig, Docetaxel and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT07225946 by Janssen Research & Development, LLC, with 800 participants planned, started 2025-12-19 and due to reach its primary completion in 2027-11-19. Interventions recorded: Pasritamig, Docetaxel and Prednisone/Prednisolone.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07225946
- Phase: 3
- Setting: A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT07225946: https://clinicaltrials.gov/study/NCT07225946

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pasritamig](https://onco.cc/drugs/pasritamig/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07225946.json